Aerie Pharmaceuticals Inc (OQ:AERI)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 4301 Emperor Blvd Ste 400
DURHAM NC 27703-7615
Tel: N/A
Website: www.aeriepharma.com
IR: See website
<
Key People
Vicente Anido
Chairman of the Board, Chief Executive Officer
Thomas A. Mitro
President, Chief Operating Officer
Casey C. Kopczynski
Co-Founder, Chief Scientific Officer
Richard J. Rubino
Chief Financial Officer, Treasurer, Secretary
Eric Carlson
Vice President - Research & Development
John LaRocca
General Counsel and Assistant Secretary
Business Overview
Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan). The Company's product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Its Rhopressa is a once-daily eye drop. Rhopressa inhibits Rho kinase (ROCK), and the norepinephrine transporter (NET), which are both biochemical targets for lowering IOP. Its Roclatan is a once-daily, fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with open-angle glaucoma. The Company is engaged in conducting Phase III clinical trial for Roclatan.
Financial Overview
For the three months ended 31 March 2019, Aerie Pharmaceuticals Inc revenues increased from $0K to $10.9M. Net loss increased 18% to $48M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative -Other increase of 28% to $27.2M (expense), Research and development - Other increase of 39% to $15.2M (expense).
Employees: 353 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $970.15M as of Mar 31, 2019
Annual revenue (TTM): $35.03M as of Mar 31, 2019
EBITDA (TTM): -$214.58M as of Mar 31, 2019
Net annual income (TTM): -$239.82M as of Mar 31, 2019
Free cash flow (TTM): -$187.51M as of Mar 31, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 45,917,834 as of May 1, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization